Ziegler R G, Rossi S C, Fears T R, Bradlow H L, Adlercreutz H, Sepkovic D, Kiuru P, Wahala K, Vaught J B, Donaldson J L, Falk R T, Fillmore C M, Siiteri P K, Hoover R N, Gail M H
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA.
Environ Health Perspect. 1997 Apr;105 Suppl 3(Suppl 3):607-14. doi: 10.1289/ehp.97105s3607.
Rapid and simple enzyme immunoassays (EIAs) were recently developed to measure 2-hydroxyestrone and 16alpha-hydroxyestrone in unextracted urine. The balance between these competing estrogen metabolism pathways may serve as a biomarker of breast cancer risk. Before testing these assays in epidemiologic studies, we evaluated their reproducibility, and validity relative to gas chromatography-mass spectroscopy (GC-MS). Overnight 12-hr urine collections from five midfollicular premenopausal women, five midluteal premenopausal women, and five postmenopausal women were aliquoted and stored at -70 degrees C. Two aliquots from each woman were assayed with the EIAs in a random, blinded order, monthly over 4 months and 1 year later. Reproducibility over 4 months was good for both metabolites in premenopausal women (coefficient of variation = 8-14%) and satisfactory in postmenopausal women (approximately 19%). Reproducibility over 12 months remained good in premenopausal women, but was poor in postmenopausal women, with mean readings increasing 50 to 100%. Wide variation in estrogen metabolite levels enabled a single EIA measurement to characterize individual differences among premenopausal women in midfollicular (intraclass correlation coefficient = 98-99%) and midluteal phase (85-91%). A narrower range in metabolite levels among postmenopausal women reduced discrimination (78-82%). The correlation between EIA and GC-MS measurement was excellent for both metabolites (r>0.9), except for 2-hydroxyestrone in postmenopausal women (r=0.6). Analysis of absolute agreement suggested that both EIAs were less sensitive than GC-MS, and each detected nonspecific background. The low concentration of estrogen metabolites in urine from postmenopausal women may explain the problems with reproducibility and validity in this menstrual group. Accordingly, more sensitive EIAs have been developed and are now being evaluated.
近期开发出了快速简便的酶免疫测定法(EIA),用于测量未提取尿液中的2-羟基雌酮和16α-羟基雌酮。这些相互竞争的雌激素代谢途径之间的平衡可能作为乳腺癌风险的生物标志物。在流行病学研究中测试这些测定法之前,我们评估了它们的可重复性以及相对于气相色谱-质谱联用仪(GC-MS)的有效性。收集了5名卵泡中期绝经前女性、5名黄体中期绝经前女性和5名绝经后女性的12小时过夜尿液样本,进行等分并储存在-70摄氏度下。从每位女性的样本中取出两份,按照随机、盲法的顺序,在4个月内每月以及1年后用EIA进行检测。绝经前女性的两种代谢物在4个月内的可重复性良好(变异系数=8-14%),绝经后女性的可重复性令人满意(约19%)。绝经前女性在12个月内的可重复性仍然良好,但绝经后女性的可重复性较差,平均读数增加了50%至100%。雌激素代谢物水平的广泛差异使得单次EIA测量能够表征卵泡中期(组内相关系数=98-99%)和黄体中期(85-91%)绝经前女性之间的个体差异。绝经后女性代谢物水平范围较窄,降低了鉴别能力(78-82%)。除绝经后女性的2-羟基雌酮外(r=0.6),两种代谢物的EIA与GC-MS测量之间的相关性都非常好(r>0.9)。绝对一致性分析表明,两种EIA都不如GC-MS敏感,且每种方法都检测到了非特异性背景。绝经后女性尿液中雌激素代谢物浓度较低可能解释了该月经组中可重复性和有效性方面的问题。因此,已经开发出了更灵敏的EIA,目前正在进行评估。